期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氨基葡萄糖在骨性关节炎治疗中的应用 被引量：7

Application of glucosamine in management of osteoarthritis
下载PDF
导出
摘要 骨性关节炎是一种常见的慢性关节疾病,治疗方法种类繁多,但尚缺乏理想的药物来逆转疾病的进程,氨基葡萄糖由结合氨基的单糖、黏多糖和壳多糖组成,是参与关节内多种分子的结构组成。近10多年来,氨基葡萄糖已广泛用于临床治疗骨性关节炎。本文就氨基葡萄糖的药动学、药理作用和临床应用作一综述。 Osteoarthritis is a common, chronic arthritis disease. Despite of being many measurements for its treatment, modifying-osteoarthritis medicine has not come into being for reversing the disease process. Glucosamine is composed of aminobound monosaccharide, mucopolysaccharide and chitin participates in forming the structures of several articular moleculars in joints. During recent ten years, glucosamine has been widely applied to treat osteoarthritis. This review discusses the pharmacokinetics, pharmacologic effects and clinical application of glucosamine.
作者 吴子英 李云霞 陈世益
机构地区 复旦大学运动医学中心 复旦大学附属华山医院运动医学与关节镜外科
出处 《上海医药》 CAS 2012年第8期8-11,共4页 Shanghai Medical & Pharmaceutical Journal
关键词 骨性关节炎 氨基葡萄糖 药动学 药理学 临床应用 osteoarthritis glucosamine pharmacokinetics pharmacology clinical application
分类号 R684 [医药卫生—骨科学]
  • 相关文献

参考文献30

  • 1Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) [J]. Ann Rheum Dis, 2003, 62(12): 1145-1155.
  • 2Pastorinia E, Rotinib R, Guardiglia M, et al. Development and validation of a HPLC-ES-MS/MS method for the determination of glueosamine in human synovial fluid [J]. J Pharm Biomed Anal, 2009, 50(5): 1009-1014.
  • 3Monauni T, Zenti MG, Cretti A, et al. Effects of glucosamine infusion on insulin secretion and insulin action in humans [J]. Diabetes, 2000, 49(6): 926-935.
  • 4Pouwels M J, Jacobs JR, Span PN, et al. Short-term glucosamine infusion does not affect insulin sensitivity in humans [J]. J Clin Endocrinol Metab, 2001, 86(5): 2099- 2103.
  • 5Rotta Pharmaceuticals. Glucosamine sulfate: summary of product characteristics [M]. Milan: Rotta Pharmaceuticals, 1999, 2423-2430.
  • 6Setnikar I, Giacchetti C, Zanolo G. Pharmacokinetics of glucosamine in the dog and man [J]. Arzneimittel-Forschung, 1986, 36(4): 729-735.
  • 7Setnikar I, Giacchetti C, Zanolo G. Absorption, distribution and excretion of radioactivity after a single intravenousor oral administration of [14C]-glucosamine to the rat [J]. Pharmacotherapeutica, 1984, 3(8): 538-558.
  • 8Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate [J]. Arzneimittel- Forschung, 2001, 51(9): 699-725.
  • 9Persiani S, Rotini R, Trisolino G, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose [J]. Osteoarthritis Cartilage, 2007, 15(7): 764-772.
  • 10Laverty S, Sandy JD, Celeste C, et al. Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses [J]. Arthritis Rheum, 2005, 52(1): 181-191.

同被引文献60

  • 1查振刚,姚平,吴昊,刘宁,黄耀熊.硫酸氨基葡萄糖预防兔膝骨关节炎的实验研究[J].中国新药杂志,2004,13(9):793-796. 被引量：9
  • 2Cifuentes DJ,Rocha LG,Silva LA,et al.Decrease in oxidative stress and histological changes inducedby physical exercise calibrated in rats with os- teoarthritis induced by monosodium iodoacetate[J].Os- teoarthritis Cartilage, 2010,18(8) : 1088-1095.
  • 3Scott JL, Gabrielides C,Davidson RK,et al.Super- oxide dismutase downregulation in osteoarthritis pro- gression and end-stage disease [J].Ann Rheum Dis, 2010,69(8) : 1502-1510.
  • 4REGINSTER J Y, DEROISYR, ROVATI L C, et al.Long-term effects of glucosamine sulphate on os- teoarthritis progression: arandomised, placebo -con- trolled clinical trial [J].Lancet, 2010,357 (9252) : 251 - 256.
  • 5Vangsness Jr, C. Spiker, W. Erickson, J. A review ofevidence-based medicine for glucosamine and chon- droitinsulfate use in knee osteoarthritis [J]. Arthroscopy, 2009, 25 (1): 86-94.
  • 6Zhang W, Nuki G, Moskowitz R W,et al.OARSI recommendations for the management of hip and knee osteoarthritis:part III :Changes in evidence following systematic cumulative update of research published through January 2009 [J]. Osteoarthritis Cartilage, 2010, 18(4) :476-499.
  • 7McAlindon T E,Bannuru R R.OARSI recommendations for the management of hip and knee osteoarthritis:the semantics of differences and changes[J].Osteoarthritis Cartilage,2010,18(4):473-476.
  • 8Reginster J V,Deroisy R,Rovati L C,et al.Longterm effects of glucosamine sulfate on osteoarthritis progression:a randomized,phcebo-controlled clinical trial[J].Lancet,2001,357(27):251-256.
  • 9Gary S,Fiveseteia Yeo.Apoptosis in rheumatoid arthritis synovium[J].J Chin Invest,1995,96(9):1631-1638.
  • 10Wandel S,Juni P,Tendal B,et al.Effects of glucosamine,chondroitin,or placebo in patients with osteoarthritis of hip or knee:network meta-analysis[J].BMJ,2010(341):4675.

引证文献7

二级引证文献24

上海医药
2012年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部